Clinical trial
Olanzapine Treated Adolescents With Schizophrenia or Bipolar I Disorder
NCT00113594 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00113594 |
|---|---|
| Title | Olanzapine Treated Adolescents With Schizophrenia or Bipolar I Disorder |
| Official title | Population Pharmacokinetic Study in Adolescent Patients With Schizophrenia or Bipolar I Disorder Treated With Olanzapine |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Schizophrenia, Bipolar Disorder |
| Intervention type | Drug |
| Interventions | Olanzapine |
| Enrollment | 100 |
| Start date | Jun 1, 2005 |
| Completion | Mar 1, 2006 |
| First posted | Jun 10, 2005 |
| Last update posted | Nov 6, 2007 |
| Countries | Puerto Rico, Russia, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: